The Food and Drug Administration (FDA) recently made long-awaited progress toward protecting patients from interventions involving human cell- and tissue-based products (HCT/P) of unknown safety and efficacy.

[pdf-embedder url=”https://www.nsorm.com/wp-content/uploads/2018/07/Regenerative-Medicine-Regulation.pdf” title=”Regenerative Medicine Regulation”]